Cat. No.: HY-126144

GSK-3β inhibitor 1

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC₅₀ of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats.

For research use only. We do not sell to patients.

Purity: 98.82%
CAS No.: 187325-53-7
Formula: C₁₄H₁₀N₂O
Molecular Weight:222.25

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

GSK-3β inhibitor 1 Chemical Structure

CAS No.: 187325-53-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC₅₀ of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats^[1].

IC₅₀ & Target^[1]

GSK-3β

4.9 nM (IC₅₀)

All GSK-3 Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	47.97 μM Compound: 3a	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30902399]

In Vitro

GSK-3β inhibitor 1 is found to effectively occupy hydrophobic cleft of the allosteric binding site. ^[1].
GSK-3β inhibitor 1 (0.1,1,10 μM, 24 h) is nontoxic against PBMCs^[1].
GSK-3β inhibitor 1 (1.56-100 μM, 72 h) inhibits proliferation of A549 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

human PBMCs
Concentration:

0.1,1,10 μM
Incubation Time:

24 h
Result:

Was nontoxic against PBMCs even at concentrations that are much higher than respective IC₅₀ value in functional GSK-3β assay.

Cell Cytotoxicity Assay^[1]

Cell Line:

A549 cells
Concentration:

1.56 -100 μM
Incubation Time:

72 h
Result:

Inhibited proliferation of A549 cells with IC₅₀ of 47.97 μM.

In Vivo

GSK-3β inhibitor 1 (50 mg/kg, i.p., 30 min prior to glucose challenge) effectively prevents increase in blood glucose levels in HFD+STZ diabetic rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HFD+STZ diabetic rats ^[1].

Dosage:

50 mg/kg

Administration:

i.p., 30 min prior to glucose challenge

Result:

Vehicle-treated diabetic rats developed persistent hyperglycemic response. Administration of GSK-3β inhibitor 1 30 min prior to glucose challenge effectively prevented increase in blood glucose levels.

Chemical Information

CAS No. 187325-53-7
Appearance Solid
Molecular Weight 222.25
Formula C₁₄H₁₀N₂O
Color Yellow to orange
SMILES

O=C1NC2=CC=CC=C2/C1=C/C3=NC=CC=C3
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All WB

Sort by:

Journal Impact Factor

Acta Pharm Sin B

2025 Dec 29.
Br J Cancer

DRD4 promotes chemo-resistance and cancer stem cell-like phenotypes by mediating the activation of the Akt/β-catenin signaling axis in liver cancer. [Abstract]

2024 Oct;131(7):1212-1223. PMID: 39174739
Drug Des Devel Ther

Ginsenoside Rg3 protects mouse leydig cells against triptolide by downregulation of miR-26a. [Abstract]

2019 Jun 24:13:2057-2066. PMID: 31296984

GSK-3β inhibitor 1 purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2019 Jun 24:13:2057-2066. [Abstract]

MLTC-1 cells are treated with Rg3 (0, 10, 20 μM) or Rg3 (20 μM) plus GSK3β inhibitor 1 (20 nM) for 24 hrs. Expression level of GSK3β in MLTC-1 cells is detected with Western blotting. The relative expression of GSK3β is quantified via normalization to β-actin.
J Enzyme Inhib Med Chem

PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1-AKT-mTOR/Bcl2 pathway. [Abstract]

2023 Dec;38(1):2230388. PMID: 37439326

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (149.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.4994 mL

22.4972 mL

44.9944 mL

5 mM

0.8999 mL

4.4994 mL

8.9989 mL

10 mM

0.4499 mL

2.2497 mL

4.4994 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lozinskaya NA, et al. Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors. Bioorg Med Chem. 2019 May 1;27(9):1804-1817. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.4994 mL	22.4972 mL	44.9944 mL	112.4859 mL
	5 mM	0.8999 mL	4.4994 mL	8.9989 mL	22.4972 mL
	10 mM	0.4499 mL	2.2497 mL	4.4994 mL	11.2486 mL
	15 mM	0.3000 mL	1.4998 mL	2.9996 mL	7.4991 mL
	20 mM	0.2250 mL	1.1249 mL	2.2497 mL	5.6243 mL
	25 mM	0.1800 mL	0.8999 mL	1.7998 mL	4.4994 mL
	30 mM	0.1500 mL	0.7499 mL	1.4998 mL	3.7495 mL
	40 mM	0.1125 mL	0.5624 mL	1.1249 mL	2.8121 mL
	50 mM	0.0900 mL	0.4499 mL	0.8999 mL	2.2497 mL
	60 mM	0.0750 mL	0.3750 mL	0.7499 mL	1.8748 mL
	80 mM	0.0562 mL	0.2812 mL	0.5624 mL	1.4061 mL
	100 mM	0.0450 mL	0.2250 mL	0.4499 mL	1.1249 mL

Keywords

GSK-3β inhibitor 1

4 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

GSK-3β inhibitor 1

Bioactive Compound Library Max

Bioactive Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

MCE Bioactive Compound Library

Covalent Screening Library Plus

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) GSK-3β inhibitor 1

All GSK-3 Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

GSK-3β inhibitor 1 Related Classifications

HY-126144 Related Classifications